Why the study?
Does trimetazidine improve cardiac function, serum glucose, lipid metabolism, and clinical symptoms in diabetic patients with coronary heart disease?
Does trimetazidine improve cardiac function, serum glucose, lipid metabolism, and clinical symptoms in diabetic patients with coronary heart disease?
Trimetazidine may improve cardiac function and metabolic parameters in diabetic patients with coronary heart disease, though it does not appear to affect triglycerides, HDL cholesterol, or exercise tolerance.
Supports trimetazidine in diabetic CHD to improve function and metabolism; extends evidence clarifying no benefit on triglycerides, HDL or exercise tolerance.
=0.01). However, there were no significant differences in serum triglyceride level, high-density lipoprotein cholesterol, exercise tolerance between the TMZ group and the control group. Conclusion TMZ treatment in diabetic patients with coronary heart disease is effective to improve cardiac function, serum glucose and lipid metabolism and clinical symptoms.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: